Imaging biomarkers in neurodegeneration: current and future practices

Alzheimer’s Research & Therapy

Rikki Lissaman¹  Mar Estarellas²  Joana B. Pereira³  David Berron³  Nick C. Fox⁴  Daniel Jiménez⁴  Antoinette O’Connor⁴  Ross W. Paterson⁴  Stephen F. Carter⁵  Emma Coomans⁶  Ashwin V. Venkataraman⁷  Matthew J. Betts⁸  Anne Maass⁸  William Jagust⁹  Helen Beaumont^1,10  Eimear McGlinchey^1,11  Michael Schöll^1,12  Meera Srikrishna^1,12  Peter N. E. Young^1,12 

[1] Cardiff University Brain Research Imaging Centre (CUBRIC), School of Psychology;Centre for Medical Image Computing (CMIC), Department of Computer Science & Department of Medical Physics and Biomedical Engineering, University College London;Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University;Dementia Research Centre, UCL Institute of Neurology, University College London;Department of Psychiatry, School of Clinical Medicine, University of Cambridge;Department of Radiology and Nuclear Medicine, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, Amsterdam UMC;Division of Brain Sciences, Imperial College London;German Center for Neurodegenerative Diseases (DZNE);Helen Wills Neuroscience Institute, University of California;Neuroscience and Aphasia Research Unit, Division of Neuroscience and Experimental Psychology, The University of Manchester;Trinity College Dublin, The University of Dublin;Wallenberg Centre for Molecular and Translational Medicine and the Department of Psychiatry and Neurochemistry, University of Gothenburg, Sahlgrenska University Hospital;

关键词: Neurodegenerative diseases;    Neuroimaging;    PET;    MRI;    Alzheimer’s disease;    Machine learning;   

DOI  :  10.1186/s13195-020-00612-7

来源: DOAJ

【 摘 要 】

Abstract There is an increasing role for biological markers (biomarkers) in the understanding and diagnosis of neurodegenerative disorders. The application of imaging biomarkers specifically for the in vivo investigation of neurodegenerative disorders has increased substantially over the past decades and continues to provide further benefits both to the diagnosis and understanding of these diseases. This review forms part of a series of articles which stem from the University College London/University of Gothenburg course “Biomarkers in neurodegenerative diseases”. In this review, we focus on neuroimaging, specifically positron emission tomography (PET) and magnetic resonance imaging (MRI), giving an overview of the current established practices clinically and in research as well as new techniques being developed. We will also discuss the use of machine learning (ML) techniques within these fields to provide additional insights to early diagnosis and multimodal analysis.

【 授权许可】

Unknown